| Identification | Back Directory | [Name]
OHM1 | [CAS]
1450995-09-1 | [Synonyms]
OHM1
Pentanediamide, 2-[(3S)-3-methyl-4-[(2S)-4-methyl-2-[(3S)-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-1-oxopentyl]-2-oxo-1-piperazinyl]-, (2S)- | [Molecular Formula]
C24H42N6O5 | [MOL File]
1450995-09-1.mol | [Molecular Weight]
494.63 |
| Hazard Information | Back Directory | [Uses]
OHM1 is an analog of HIF1α CTAD that inhibits its binding with p300/CBP. OHM1 targets CH1 domain with an affinity of 0.53 μM[1]. | [in vivo]
OHM1 (15 mg/kg; i.p.; every other day for 15 injections) reduces MDA-MB-231 tumor volume in mice[1]. | Animal Model: | BALB/c mice, MDA-MB-231 xenograft model[1] | | Dosage: | 15 mg/kg | | Administration: | Intraperitoneal injection, every other day for 15 injections | | Result: | Reduced the median tumor volume by roughly 50% compared with the untreated group. Did not cause measurable changes in animal body weight or other signs of toxicity in tumor-bearing animals, nor increased the metastasis rate. |
| [References]
[1] Lao BB, et al. In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics. Proc Natl Acad Sci U S A. 2014 May 27;111(21):7531-6. DOI:10.1073/pnas.1402393111 |
|
|